Inclusion Criteria:

- Healthy postmenopausal women with a body mass index (BMI) of 25 kg/m^2 or greater

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Karnofsky 70% or
above

- Leukocytes >= 3,000/uL

- Absolute neutrophil count (ANC) >= 1,500/uL

- Platelets >= 100,000/uL

- Total bilirubin =< 2.0 mg/dL

- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 times upper
limit of normal (ULN)

- Creatinine =< 1.0 times ULN

- Ability and willingness to limit resveratrol-containing foods to no more than one
serving each per day for about 14 weeks

- Negative mammogram or negative workup of mammographic findings within prior 12 months
prior to enrollment for women >= 50 years of age

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Have had invasive cancer(s) within the past 5 years except non-melanoma skin cancer

- Within 3 months of or concurrent usage of any other investigational agents

- History of allergic reactions attributed to resveratrol

- Unwilling or unable to refrain from taking herbal medicines and dietary supplements

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Within 3 months of or concurrent estrogen or progesterone replacement therapy, oral
contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin
inhibitors, or antiandrogens; vaginal estrogen is acceptable.

Within 3 months of or concurrent usage of tamoxifen, raloxifene, other selective
estrogen-receptor modulators, or aromatase inhibitors

- Regular usage (more than 2 times a week) of estrogenic supplements or herbal remedies
(e.g., Remifemin, black cohosh, red clover, dong quai, soy isoflavones,
dehydroepiandrosterone [DHEA], flaxseed, diindolylmethane [DIM], genistein, and
daidzein) within the past 3 months or concurrently; dietary consumption of
phytoestrogens/isoflavones (such as soy, tofu, millet, barley, natto, tempeh, miso,
soy milk, soy sauce) is acceptable as these sources are not concentrated

- Concurrent use of anti-diabetic drugs such as:

- Insulin

- Sulfonylureas (e.g., glipizide, glyburide, or glimepiride)

- Meglitinides (e.g., repaglinide or nateglinide)

- Biguanides (e.g., metformin)

- Thiazolidinediones (e.g., rosiglitazone or pioglitazone)

- Alpha-glucosidase inhibitors (e.g., acarbose or miglitol)

- Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin)

- Concurrent use of warfarin or phenytoin